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Background. Recently, a -168ARG polymorphism in the MHC class II transactivator gene (MHC2TA) was shown to be
associated with increased susceptibility to myocardial infarction (MI). Aim. To confirm the association between the MHC2TA -
168ARG polymorphism and MI and to study its putative role for microalbuminuria, the metabolic syndrome (MetS) and
cardiovascular mortality. Materials and Methods. Using an allelic discrimination method we genotyped 11,064 individuals
from three study populations: 1) 4,432 individuals from the Botnia type 2 diabetes (T2D) study, 2) 1,222 patients with MI and
2,345 control subjects participating in the Malmo ¨ Diet and Cancer study and comprising an MI case-control sample, and 3)
3,065 T2D patients from the Local Swedish Diabetes registry. Results. No association between the -168ARG polymorphism in
MHC2TA and MI was observed. However, in the Botnia cohort the AG/GG genotypes were associated with cardiovascular
mortality after MI (1.78 [1.09–2.92], p=0.02). In addition, the AG/GG genotypes were more common in subjects with MetS
(40.1% vs. 36.9%, p=0.03) and in non-diabetic subjects with microalbuminuria (45.4% vs. 36.5%, p=0.003) compared to
control subjects. Conclusions. A polymorphism in MHC2TA was associated with cardiovascular mortality and predictors of
cardiovascular mortality, microalbuminuria and MetS.
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INTRODUCTION
Cardiovascular disease is the leading cause of death in Sweden and
inmost Westerncountries.Almost50%ofdeceasedindividuals died
due to cardiovascular causes in Sweden 2005 (Swedish National
Board of Health and Welfare http://www.socialstyrelsen.se). Both
geneticand environmental factorsmodifythe riskforcardiovascular
diseases including myocardial infarction (MI) [1],smoking, dyslipi-
daemia, diabetes, obesity and hypertension, are present in up to
90% of patients with MI [2,3]. Family history of MI has been
shown to be a strong independent risk factor for coronary heart
disease [4–7].
Microalbuminuria is an established risk marker for cardiovas-
cular morbidity and mortality both in diabetic [8] and non-
diabetic patients [9]. Inflammation is believed to play a major role
in the pathogenesis of both microalbuminuria [10] and MI [11].
Insulin resistance has been proposed as a common denominator
for these conditions, and has also been related to subclinical
chronic inflammation [12].
A –168 ARG polymorphism in the MHC class II transactivator
gene (MHC2TA) was recently found to be associated with MI,
rheumatoid arthritis and multiple sclerosis [13]. The -168 ARG
polymorphism was associated with lower expression of MHC2TA
after stimulation of leukocytes with interferon-c in humans and
differences in expression of MHC class II molecules in different
rat strains. Because of the role of MHC class II molecules in
recognition of antigen molecules, genes like MHC2TA that can
influence expression of MHC class II, are also candidate genes for
autoimmune diseases [13].
To address this issue, we searched for any association between
MHC2TA -168 ARG polymorphism and cardiovascular morbid-
ity and mortality as well as their predictors, microalbuminuria and
the metabolic syndrome (MetS).
MATERIALS AND METHODS
Study Subjects
Patients were selected from three large populations in Finland and
Sweden; the Botnia study, the Malmo ¨ Diet and Cancer Study
(MDC) and the Diabetes Registry in Southern Sweden (DR). The
protocols were approved by local Ethics committees, and informed
consent was obtained from all subjects.
The Botnia Study The Botnia Study was initiated in 1990
and represents a large population-based type 2 diabetes (T2D)
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genes increasing susceptibility to T2D, MetS and associated
complications. Details of the study cohort, sampling strategy as
well as anthropometric and metabolic measurements have been
described earlier [14,15]. At the baseline examination, a structured
questionnaire was completed by specially trained nurses, covering
information about diseases other than T2D (particularly hyper-
tension, coronary heart disease, MI and stroke) and data on
smoking habits. Both previous and current smokers were recorded
as smokers. Diagnosis of MI was always established in the hospital.
Microalbuminuria was defined as urinary albumin excretion rate
.20 mg/min in an overnight urine collection.
Total and cardiovascular mortality were assessed with a median
follow up time of 7.9 years and the mortality data was obtained
from the central death-certificate registry in Finland. Cardio-
vascular mortality was classified using the 9th revision of the
International Classification of Diseases (cardiovascular diagnosis
codes 390–459) before 1997 and the 10th revision (codes 100–199)
thereafter. Causes of death were classified as 1) cardiovascular
death (coronary heart disease), cerebrovascular disease (including
both thrombotic stroke and cerebral haemorrhage) or other
cardiovascular (including pulmonary embolism, abdominal aortic
aneurysm, hypertensive complications, general atherosclerosis and
peripheral artery disease with gangrene) or 2) other causes of death
(neoplasm, violent or other). MetS was defined according to the
National Cholesterol Education Program (NCEP) [16].
In total, 4,432 individuals were genotyped for the MHC2TA -
168 ARG polymorphism including 2,864 individuals without
diabetes mellitus and 1,557 with T2D. Data on MI was available
in 97% and on microalbuminuria in 64% of the subjects. Data on
cardiovascular mortality was available for all patients.
The MI case- control population from the Malmo ¨ diet and
cancer study (MDC) The Malmo ¨ Diet and Cancer study
population (MDC) [17] includes 28,098 randomly selected men
(born 1923–1945) and women (born 1923–1950) living in the city
of Malmo ¨ (population 250,000) in Sweden. A baseline exami-
nation was carried out between 1991 and 1996 encompassing
a comprehensive assessment of lifestyle factors, heredity, medica-
tion as well as previous and current diseases. On December 31
st,
2000 the study population was checked against the Swedish
National Board of Health and Welfare’s National Patient Registry
and Cause of Death Registry. MI cases (first MI) were identified in
the Swedish Patient Registry or in the Swedish Cause of Death
Registry; using ICD 9–10 codes 410 and I21 in the Swedish
Patient Registry and 410–414 and I21–I25 in the Swedish Cause
of Death Registry.
Two age- (61 year) and gender-matched controls without MI
from MDC were assigned to each MI patient, resulting in a case-
control material consisting of 1,244 MI patients and 2,488
controls. Of total 3,732 individuals, 3,657 were successfully
genotyped for the ARG polymorphism in MHC2TA. Diabetes
diagnosis was defined as self reported earlier diagnosis, fasting
blood glucose $ 6.1 mmol/l and/or treatment for earlier
diagnosed diabetes mellitus.
Diabetes registry in Southern Sweden (DR) 3,065 T2D
patients from a local diabetes registry in Southern Sweden [18],
most of them enrolled at the Department of Endocrinology,
University Hospital MAS, Malmo ¨, were selected and genotyped
for the MHC2TA -168 ARG polymorphism. Data on MI was
obtained from the patient records and was available in 77% and
on microalbuminuria in 70% of the subjects.
Analytical techniques HbA1c, total cholesterol, HDL-
cholesterol, triglycerides and P-creatinine were measured with
standard laboratory methods. A detailed description of the
methods are found elsewhere [15,18,19]. The urinary albumin
concentration was in DR determined first by immuno-
nephelometric method (Beckman Instruments, CA, USA) until
1998, and thereafter by an immunoturbimetric method (Beckman
Coulter, Beckman Instruments, CA, USA). In the Botnia study,
urine albumin concentration was determined with a radioimmuno-
assay with a detection limit of 2 mg/l. Microalbuminuria was
defined as AER of $20 mg/min.
Genotyping In total 11,064 individuals were successfully
genotyped for the -168 A/G polymorphism (rs3087456) using
allelic discrimination method on the ABI 7900 instrument
(Applied Biosystems, Foster City, CA). Risk genotypes were
defined according to earlier published report [13]. The genotyping
success rate was 97.9, 98.0 and 99.0% in Botnia, MDC and DR
cohorts, respectively.
Statistical methods
Data are presented as mean 6 SD or as median [25
th–75
th]
percentile. Chi-square tests were used to analyze differences
between allele- and genotype frequencies. To test differences
between group means, the Student’s two-tailed t-test was used
for normally distributed values and Mann-Whitney U-test for
non-normally distributed medians. In order to identify factors
associated with MI and microalbuminuria, a multiple logistic
regression analysis with forward selection was performed. Because
of the nature of Botnia cohort as a family collection, the analyses
were adjusted for the family relations. For the mortality analyses,
clinical variables together with MHC2TA genotypes were entered
into a forward stepwise Cox regression model adjusted for sex, age
and family relations.
All data were analyzed with a NCSS 2004 (NCSS statistical
software, Kaysville, UT, USA). A p-value of ,0.05 was considered
statistically significant. Power analysis was made using Genetic
Power Calculator [20].
RESULTS
The clinical characteristics of the study groups are given in
Table 1. The genotype and allele frequencies of the MHC2TA
polymorphism were similar in patients with or without MI,
regardless of the study population and T2D status (Table 2). No
association with T2D was observed, neither in the Finnish
(Botnia), nor in the Swedish (MDC or DR) cohorts.
No correlation between the MHC2TA -168 AG/GG genotypes
and cardiovascular mortality was found in the Botnia Study
population (HR 0.96 [0.75–1.22], p=0.74) (Table 3). As the
MHC2TA polymorphism was earlier shown to be associated with
MI, we performed a subgroup analysis of individuals with previous
history of MI. In fact, among these patients the MHC2TA AG/GG
genotypes were associated with increased risk of cardiovascular
death compared with AA genotype carriers (HR 1.76 [1.09–2.82],
p=0.02) (Table 3, Figure 1). We also tested the MHC2TA GG
genotype against the AA or AG genotypes and found that the GG
genotype was protective against cardiovascular death in the whole
group (HR 0.38 [0.16–0.92], p=0.03), but not in patients with
previous MI (HR 0.45 [0.49–4.16], p=0.48).
The MHC2TA AG/GG genotypes were more frequently found
among patients with MetS (40.1 vs. 36.9%, p=0.030) as well as
among non-diabetic individuals with microalbuminuria in the
Botnia cohort (50.0% vs. 36.0%, p=0.003, Table 2). In contrast,
the AG/GG genotypes were not associated with microalbumi-
nuria among T2D patients, neither in the Botnia, nor the DR
cohort (Table 2). Correspondingly, logistic regression analysis with
age, waist-hip ratio, fasting insulin, systolic- and diastolic blood
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PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e64pressure, smoking, gender and MHC2TA AG/GG genotypes as
independent factors, revealed the AG/GG genotypes as risk
factors for microalbuminuria in non-diabetic subjects (OR 2.07
Table 1. Clinical characteristics of the study subjects.
..................................................................................................................................................
Botnia MDC DR
Non-diabetic T2D p Non-diabetic T2D p T2D
Male/Female 1307/1566 731/828 0.37 2492/891 202/72 0.98 1766/1299
Age (Yrs.) 54613 67612 ,1610
26 63676 3 66 0.14 63612
BMI (Kg/m
2)2 6 . 2 64.1 28.164.7 ,1610
26 26.263.7 28.164.3 ,1610
26 29.565.6
SBP (mmHg) 135620 150622 ,1610
26 147621 153619 7610
25 144620
DBP (mmHg) 81610 83611 ,1610
26 88610 88610 0.41 80611
HbA1c (%) 5.560.5 7.561.7 ,1610
26 4.860.4 (N=575) 6.861.8 (N=82) ,1610
26 6.961.7
Age at onset of Diabetes (Yrs.) - 59614 - - - 54613
Smoking (%)* 38.0 36.7 0.40 69.1 75.9 0.02 50.1























































Table 2. The genotype frequencies of the MHC2TA -168 ARG polymorphism in different study populations according to history of
previous MI and microalbuminuria status.
..................................................................................................................................................
MI p Microalbuminuria (MALB) p
MI+ MI2 MALB+ MALB2
AA/AG/GG AA/AG/GG AA/AG/GG AA/AG/GG
Botnia
Non-diabetic 63.4/33.0/3.6 (N=112) (62.8/33.3/3.9) (N=2686) 0.90 (49.5/45.5/5.0) (N=99) (64.0/32.4/3.6) (N=1940) 0.003
T2D (59.2/38.0/2.7) (N=184) (59.7/36.0/4.2) (N=1326) 0.90 (58.9/38.8/2.3) (N=129) (63.6/32.4/4.0) (N=756) 0.33
MDC
Non-diabetic (58.0/35.7/6.3) (N=1071) (55.7/37.4/6.9) (N=2312) 0.21 - - -
T2D (45.7/43.7/10.6) (N=151) (52.8/42.3/4.9) (N=123) 0.24 - - -
Diabetes registry
T2D (57.0/37.3/5.7) (N=316) (54.4/39.1/6.4) (N=1974) 0.44 (53.8/39.4/6.8) (N=827) (56.4/37.1/6.4) (N=1311) 0.23
The numbers are allele frequencies (%) and number of patients. P-values refer to comparison between genotype frequencies of the –168ART risk genotypes (AG or GG)

































































Figure 1. Cardiovascular mortality in the Botnia cohort in patients with
previous MI according to MHC2TA -168 ARG genotypes. Kaplan Meier
survival curves illustrating a higher risk for CV mortality (HR 1.76 [1.09–
2.82], p=0.02) in AG/GG genotype carriers with previous history of MI.
doi:10.1371/journal.pone.0000064.g001
Table 3. Predictors of cardiovascular mortality among all
individuals and patients with previous MI from the Botnia
study.
......................................................................
All patients Previous MI
Male Sex 1.34 [1.00–1.80] 1.20 [0.64–2.25]
Smoking 1.42 [1.04–1.96] 1.33 [0.78–2.25]
Cholesterol (mmol/l) 1.11 [1.01–1.22] 1.10 [0.87–1.39]
HDL cholesterol (mmol/l) 0.57 [0.38–0.85] 0.76 [0.27–2.20]
SBP (mmHg)* 1.00 [0.99–1.00] 1.00 [0.98–1.01]
DBP (mmHg)* 1.00 [0.99–1.01] 0.99 [0.97–1.02]
T2D 2.97 [2.22–3.97] 2.19 [1.18–4.08]
MHC2TA (AG or GG) 0.96 [0.75–1.22] 1.76 [1.09–2.82]
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[0.80–1.84], p=0.35).
The statistical power to detect differences in risk of MI
according to genotype assuming dominant model and genotype
relative risk of 1.2 was 32.0% in Botnia, 95.1% in the MDC cohort
and 36.5% for Swedish T2D patients (from DR). The correspond-
ing figures when assuming genotype relative risk of 1.5 were 95.0,
100.0, and 92.7%. In the pooled Swedish sample the power was
97.0% assuming a relative risk of 1.2 and 100% at the level of 1.5.
DISCUSSION
The key finding of the present study was an association between
the MHC2TA -168 ARG polymorphism and cardiovascular
mortality as well as with predictors thereof, microalbuminuria
and MetS. These findings support the earlier report of association
between this polymorphism and MI [13]. However, in contrast to
the earlier study [13], the -168 ARG was not associated with MI
in our study. One possible explanation could be differences in
definition of MI. Our study consisted of population based material,
where the information of MI was collected retrospectively,
whereas the study population of Swanberg et al. was recruited
from all patients below 60 yrs. that were admitted to the hospital
for acute MI.
Microalbuminuria is a risk marker for cardiovascular disease [9]
and has been suggested to reflect a state of low-grade systemic
inflammation [21]. Several factors like high blood pressure,
hyperglycaemia, smoking, heart failure and renal atherosclerosis,
all of which themselves are associated with increased inflammatory
activity, are known to play a role in the development of micro-
albuminuria [22]. The association with microalbuminuria was,
however, restricted to non-diabetic subjects. This could reflect the
fact that in diabetic subjects other factors including hyperglycae-
mia may influence the day-to-day variation in albumin excretion.
The non-diabetic patients with microalbuminuria had several
features of MetS including higher waist to hip ratio, higher
HOMA –index, and higher blood pressure (data not shown)
compared to individuals without microalbuminuria. Accordingly,
the MHC2TA -168ARG polymorphism was also associated with
MetS.
Thus, the MHC2TA -168 ARG polymorphism influenced both
outcome and prediction of cardiovascular disease. Among patients
with previous MI, carriers of the AG or GG genotypes had
increased risk of cardiovascular death compared with AA genotype
carriers (Table 3 and Figure 1). It is known that inflammation
plays a key role in development of atherosclerosis [11] and
activated T-lymphocytes are already present in the atherosclerotic
plaque, as well as in the immediate site of plaque rupture or
superficial erosions in patients who have died due to MI or
unstable angina [23]. Our results suggest that the G-allele (and in
particular the AG genotype) could be a risk factor for
cardiovascular mortality after MI, although the mechanism
remains unclear. Swanberg et al. suggested that the G allele could
cause reduced induction of MHC class II genes thus leading to less
efficient presentation of antigens to regulatory T cells [13].
However, the previous association analysis compared AG and GG
genotype carriers to AA genotype carriers and showed that in
particular the AG (and not GG) genotype carriers were at higher
risk [13]. In contrast, the expression analysis compared a pool of
AA and AG genotype carriers to GG genotype carriers thus not
challenging the possibility of a difference between the more
common AA and AG genotypes [13]. Interestingly, we observed
that in fact the GG carriers had a lower risk for death due to
cardiovascular events compared to AA or AG genotype carriers
(HR 0.38 [0.16–0.92]). It is therefore unclear whether the risk
really is associated with less induction of the MHC II genes in
response to inflammation stimuli. To clarify this issue, expression
levels of all genotypes would therefore be of interest, especially
comparison between the AA and AG genotypes.
Taken together, despite lack of a relationship between MHC2TA
and MI in this large association study, we show that the AG/GG
genotypes of the MHC2TA -168 ARG polymorphism are
associated with microalbuminuria and features of MetS. This, in
turn, translates into an increased risk of cardiovascular mortality.
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